Performance gap between dual and non-dual eligibles grows

A significant and growing performance gap exists between dual eligible and non-dual eligible members that cannot be attributed to a health plan's quality of service, a new study by Inovalon has found. » Study results

ADVERTISEMENT

Now FDA-Approved With a New Indication for Your Members
OLYSIO^® (simeprevir) 150-mg capsule
For more information, http://www.olysio.com/hcp/
^© Janssen Therapeutics, Division of Janssen Products, LP 2015 2/15 028680-150128

Exchange plans fail to offer required smoking cessation coverage

Millions of Americans who have enrolled in health insurance marketplace plans should be provided with free tools to quit smoking, but a new report from the American Lung Association shows fewer than 20% of plan issuers are providing the appropriate coverage. » Details

CEO resignation linked to FDA drug approval process

Sarepta Therapeutics CEO Chris Garabedian resigned earlier this week, a move that may be linked to a dispute with FDA over the approval process for its new drug, according to The Wall Street Journal. » More

IN CASE YOU MISSED IT

• UnitedHealth Group's $12.8 billion purchase of Catamaran makes sense

• The risks and rewards of Medical Loss Ratio

• BioCryst receives $12 million to develop Ebola drug

Keep in touch with MHE

We value your input. Please send your comments and article ideas to [email protected].